Coronavirus Disease 2019 (COVID-19)

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the Ministry of Health.

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Content</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agencies</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agency of Canada</td>
<td>canada.ca</td>
</tr>
<tr>
<td>BC Centre for Disease Control</td>
<td>bccdc.ca</td>
</tr>
<tr>
<td>Institut national de santé publique</td>
<td></td>
</tr>
<tr>
<td>CDC: Centers for Disease Control and Prevention</td>
<td>cdc.gov</td>
</tr>
<tr>
<td>ECDC: European Centre for Disease Prevention and Control</td>
<td>ecdc.europa.eu</td>
</tr>
<tr>
<td>FDA: U.S. Food &amp; Drug Administration</td>
<td>fda.gov</td>
</tr>
<tr>
<td>Public Health England</td>
<td>gov.uk</td>
</tr>
<tr>
<td>World Health Organization</td>
<td>who.int</td>
</tr>
<tr>
<td>Other relevant government bodies / health care organizations</td>
<td>5</td>
</tr>
<tr>
<td>CIDRAP: Center for Infectious Disease Research Policy</td>
<td>cidrap.umn.edu</td>
</tr>
<tr>
<td>National Collaborating Centre for Environmental Health</td>
<td>ncceh.ca</td>
</tr>
<tr>
<td>Updated Daily</td>
<td>6</td>
</tr>
<tr>
<td>COVID-19 resources (case counts)</td>
<td>arcgis.com</td>
</tr>
<tr>
<td>COVID-19 Canada Open Data Working Group</td>
<td>COVID-19 CODWG</td>
</tr>
<tr>
<td>Johns Hopkins CCSE</td>
<td>systems.jhu.edu</td>
</tr>
<tr>
<td>NextStrain</td>
<td>nextstrain.org</td>
</tr>
<tr>
<td>Guidelines and Technical documents (updated weekly)</td>
<td>7</td>
</tr>
<tr>
<td>Section I: General Guidelines</td>
<td>7</td>
</tr>
<tr>
<td>Ontario / Canada Main Page</td>
<td>7</td>
</tr>
<tr>
<td>Reopening/Rebuilding Guidelines</td>
<td>7</td>
</tr>
</tbody>
</table>
Vaccinations- General.................................................................8
Vaccinations- Specific populations ...........................................13
Vaccinations- Adverse Effects..................................................14
Background Information/Case Definitions ...............................16
Laboratories .................................................................16
Miscellaneous Guidelines ..........................................................18
Data & Surveillance ..............................................................19
Variants – Omicron .................................................................20
Testing .................................................................20
Symptoms/Treatment .............................................................23
COVID-19 Diagnosis in Children ...........................................24
Post-COVID-19 Condition .......................................................25
Case Investigation & Contact Tracing ....................................25
Infection Prevention and Control ...........................................26

Section II: Guidelines for Health Sectors ........................................27

Healthcare Providers .............................................................27
Congregate Living (including Long-Term Care, Prisons, and Shelters) ..................................28

Section III: Guidelines for the Community .....................................29

Travel, Transport & Borders ......................................................29
Schools / Childcare .................................................................30
Mental Health /Addiction /Inequity ............................................30
Community ........................................................................31
Businesses/Workplaces ...........................................................32
Masks (Non-Medical) ..............................................................32
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Statement from the Chief Public Health Officer of Canada [07-15-2022]
- Mathematical modelling and COVID-19 [updated regularly]
- COVID-19 daily epidemiology update [updated regularly]
- COVID-19 data trends [updated regularly]

BC Centre for Disease Control | bccdc.ca

- Treatments Practice Tool #2: Definitions of Clinically Extremely Vulnerable (CEV) [updated 07-26-2022]
- Pfizer Shipping, Storage, Thawing and Use Guideline (Gray Cap) [updated 07-26-2022]

Institut national de santé publique | inspq.qc.ca

- SRAS-CoV-2 : Définitions des termes en prévention et contrôle des infections dans les milieux de soins [07-26-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les soins à domicile [07-26-2022]

CDC: Centers for Disease Control and Prevention | cdc.gov

- Information about the Pfizer-BioNTech COVID-19 vaccine [07-29-2022]
- COVID-19 hospitalization and death by age [07-29-2022]
- COVID Data Tracker Weekly Review [07-29-2022]
  - Interpretive summary: Protect those who protect us
  - “Nearly two and a half years into the COVID-19 pandemic, cases and hospitalizations have been on the rise, driven by the BA.5 lineage of the Omicron variant. More than a million people in the United States have died from COVID-19, and almost 90 million cases have been reported. The pandemic has taken a tremendous toll on healthcare providers and public health workers, who are dealing with crisis levels of stress and burnout.

  A recent CDC survey found that nearly half of U.S. public health workers reported symptoms of at least one mental health condition. Symptoms of post-traumatic stress disorder (PTSD), anxiety, and depression were highest (28%), followed by suicidal thoughts (8%). These symptoms were most common among those who worked more than 60 hours a week or spent most of their time working on COVID-19 response activities. Mental health symptoms were less common in workers who were able to take time off or whose employers increased mental health resources.

  These findings highlight the need for public health organizations to protect the mental health of their employees.”


Nearly two and a half years into the COVID-19 pandemic, cases and hospitalizations have been on the rise, driven by the BA.5 lineage of the Omicron variant. More than a million people in the United States have died from COVID-19, and almost 90 million cases have been reported. The pandemic has taken a tremendous toll on healthcare providers and public health workers, who are dealing with crisis levels of stress and burnout.

A recent CDC survey found that nearly half of U.S. public health workers reported symptoms of at least one mental health condition. Symptoms of post-traumatic stress disorder (PTSD), anxiety, and depression were highest (28%), followed by suicidal thoughts (8%). These symptoms were most common among those who worked more than 60 hours a week or spent most of their time working on COVID-19 response activities. Mental health symptoms were less common in workers who were able to take time off or whose employers increased mental health resources.

These findings highlight the need for public health organizations to protect the mental health of their employees.”
- **Cases in the U.S.** [07-28-2022]
- **COVID Data Tracker Recent Updates - 2022-07-28 - The Rates of Laboratory-Confirmed Hospitalizations by Vaccination Status tab was updated to display June 2022 rates of COVID-19-associated hospitalization comparing unvaccinated people, fully vaccinated people, and people with an additional or booster dose. The tab was also updated to include data on second boosters for adults ages 50 years and older.** [07-28-2022]
- **COVID Data Tracker Recent Updates - 2022-07-28 - The Vaccination Demographics and Vaccination Demographic Trends tabs were updated to display data on second booster doses for people 50 years and older by age, sex, and race/ethnicity.** [07-28-2022]
- **Overall US COVID-19 vaccine distribution and administration update as of Wed, 27 Jul 2022 06:00:00 EST** [07-27-2022]
- **Previous COVID-19 forecasts: deaths - 2022** [07-27-2022]
- **Operation Expanded Testing** [07-27-2022]
- **COVID-19 forecasts: deaths** [07-27-2022]
- **Global community mitigation** [07-25-2022]
- **CDC COVID-19 global response** [07-25-2022]

**ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu**

- **Communicable disease threats report, 24 - 30 July, week 30** [07-29-2022]
  - “This issue covers the period 24 -30 July and includes updates on COVID-19, monkeypox, West Nile virus, increase in hepatitis of unknown aetiology in children, mass gatherings in the Birmingham 2022 Commonwealth games, Vibrio growth, Marburg virus disease, Chikungunya, dengue, cholera, and wild poliovirus.”
- **ECDC expert consultation on knowledge and research gaps related to the COVID-19 public health response** [07-29-2022]
- **Country overview report: week 28 2022** [07-29-2022]
  - At the end of week 29, 2022 (week ending 24 July), the overall notification rate of COVID-19 cases in the EU/EEA remained high (1 016 cases per 100 000 population, 31% of pandemic maximum) albeit with a recent decreasing trend (15% decrease compared to previous week). Among people aged 65 years and above, case rates are also declining but at a slower rate (1 119 cases per 100 000 population, corresponding to a 4.2% decrease compared to the previous week) and transmission in this age group remains high at 87.3% of pandemic maximum.
  - Forecasts of cases, hospital admissions and deaths from the [European COVID-19 Forecast Hub](https://ecdc.europa.eu/en/healthtopics/COVID-19/forecasting) provide predictions for weeks 30 and 31. Compared with the previous week, decreasing trends in cases, stable trends in hospital admissions, and increasing trends in deaths are forecast for the EU/EEA overall by the end of week 31. Forecasts for individual countries may differ from those for the EU/EEA as a whole. It should be noted that forecasts of cases are considered to be increasingly unreliable due to changes in testing criteria and reporting procedures. All current forecasts, in particular case forecasts, should be treated with caution.
  - The cumulative uptake of a first booster was 63.8% (country range: 11.2–85.9%) among adults aged 18 years and older and 52.9% (country range: 9.1–69.1%) in the total population. The cumulative uptake of a second booster was 6.3% (country range: 0.0–
19.8%) among adults aged 18 years and older and 5.1% (country range: 0.0–15.6%) in the total population.

- Joint ECDC-WHO Regional Office for Europe weekly COVID-19 surveillance bulletin [07-25-2022]
- Data on the daily number of new reported COVID-19 cases and deaths by EU/EEA country [updated regularly]
- Data on COVID-19 vaccination in the EU/EEA [updated regularly]

FDA: U.S. Food & Drug Administration | fda.gov

- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- FDA roundup: July 22, 2022 [07-22-2022]
  - “On June 14, as part of the FDA’s effort to protect consumers, the agency issued a warning letter to H2 Beverages, Inc. for selling unapproved and misbranded hydrogen-infused water beverage products as drugs for use in treating or preventing COVID-19 and other diseases. Consumers concerned about COVID-19 should consult with their health care provider.”
- Medical device shortages during the COVID-19 public health emergency [updated 07-19-2022]

Public Health England | gov.uk

Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”

- Location of Public Health England (PHE) functions from 1 October 2021

World Health Organization | who.int

- WHO Director-General’s opening remarks at the COVID-19 media briefing [07-27-2022]
  - “…although the COVID-19 pandemic is far from over, we are now in a very different situation to where we were a year ago, and we have learned a number of important lessons. One of the most important is that the most effective way to save lives, protect health systems and reopen societies and economies is to vaccinate the right groups first. Even in some countries that have reached 70% vaccination coverage, if significant numbers of health workers, older people and other at-risk groups remain unvaccinated, deaths will continue, health systems will remain under pressure and the global recovery will be at risk. This is not theoretical, this is real.”
- WHO coronavirus (COVID-19) dashboard [updated regularly]

Other relevant government bodies / health care organizations

- Government of Ontario
  - COVID-19 vaccine bookings to open for children aged six months to under five years [07-21-2022]
- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
- Statistics Canada
Coronavirus Disease 2019 (COVID-19): 07/29/2022

- COVID-19: a data perspective [updated regularly]
- Travel between Canada and other countries, May 2022 [07-22-2022]

- UK Health Security Agency
  - COVID-19 testing in homelessness, domestic abuse refuge and respite room settings [07-22-2022]

- UK Medicines and Healthcare products Regulatory Agency
  - Coronavirus (COVID-19) vaccines adverse reactions [updated 07-25-2022]

- UK Office for Health Improvement and Disparities
  - COVID-19 Health Inequalities Monitoring in England tool (CHIME) [updated 07-21-2022]
  - Wider impacts of COVID-19 on health monitoring tool [updated 07-21-2022]

CIDRAP: Center for Infectious Disease Research Policy | cidrap.umn.edu
- Studies reveal racial disparities in early US COVID vaccine rollout [07-28-2022]
- News Scan for Jul 28, 2022: Smell and taste after COVID; Global flu patterns; Peanut butter Salmonella probe winds down; More avian flu in poultry
- Persistent brain fog, hair loss highlighted in long-COVID studies [07-27-2022]
- COVID hot spots shift; studies add evidence for Wuhan market origin [07-27-2022]
- News Scan for Jul 27, 2022: COVID vaccines cut risk of reinfection; Short-course antibiotics for pneumonia; More Marburg infections in Ghana
- Experts air vision for better vaccines as BA.5 expands dominance [07-26-2022]
- News Scan for Jul 26, 2022: COVID vaccine and myocarditis in kids; European AMR data; AAV2 acute hepatitis link

National Collaborating Centre for Environmental Health | ncceh.ca
- July research scan with COVID-19 sections [07-20-2022]
- June research scan with COVID-19 sections [06-15-2022]
- May research scan with COVID-19 sections [05-18-2022]

ProMED | promedmail.org
- Latest on COVID-19 [individual posts]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
• Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
• Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
• Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
• Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 07-18-2022; posted 07-19-2022

Section I: General Guidelines
Ontario / Canada Main Page
• Ontario guidance
• Canadian guidance (federal)

Reopening/Rebuilding Guidelines
Ontario
• ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
• CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.'s response to COVID-19 [updated 07-08-2022]
• AB COVID-19 public health actions [no date]
• SK Living with COVID [no date]
• MB Manitoba Pandemic Response System [no date]
• QC Coronavirus disease (COVID-19) in Québec [06-09-2022]
• NB Living with COVID-19 [no date]
• NL Current Restrictions [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NS Reopening plan [updated regularly]
• NW Restrictions and Moving Forward [no date]
• YT Forging ahead: the Yukon’s continuing response to COVID-19 [no date]
• NT Nunavut’s Path: Living with COVID-19 [no date]
• Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
• Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

ECDC
• Data on country response measures to COVID-19 [updated 06-27-2022]
• Transitioning beyond the acute phase of the COVID-19 pandemic: Approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
• COVID-19 vaccine-relevant information and planning resources [updated 07-14-2022]
• Ethical framework for COVID-19 vaccine distribution [archived] [updated 04-27-2022]

Canada (Federal)
• Planning guidance for immunization clinics for COVID-19 vaccines [07-06-2022]
• Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [06-29-2022]
• Summary of NACI statement of June 29, 2022 [06-29-2022]
• Adjusting public health measures in the context of COVID-19 vaccination [updated 06-27-2022]
• Health care provider vaccine tool kit, version 3 [06-10-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Initial guidance on a second booster dose of COVID-19 vaccines in Canada [04-05-2022]
• COVID-19 vaccine guide for youth and adults (12 years and over): Overview [02-02-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-16-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)
• BC COVID-19 vaccine eligibility [updated 07-08-2022]
• BC Spikevax™ (Moderna) [updated 07-08-2022]
• BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 07-08-2022]
• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 07-08-2022]
• BC Vaxzevria™/COVSHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 07-08-2022]
• BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 07-08-2022]
• BC COVID-19 vaccine ChAdOx1-S [recombinant] [updated 07-08-2022]
• BC Janssen shipping, storage and use guideline [updated 06-15-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 06-07-2022]
• BC Novavax shipping, storage and use guidelines [03-04-2022]
• BC Novavax redistribution guidelines [03-04-2022]
• BC Immunization manual: summary of changes: admin circular [03-04-2022]
• BC COVID-19 vaccine screening checklist [02-25-2022]
• BC Pfizer redistribution guidelines [02-08-2022]
• BC Point of care risk assessment (PCRA) [no date]
• BC Janssen redistribution guidelines [01-17-2022]
• BC Regulated and unregulated health professionals SARS-CoV-2 immunization order [01-09-2022]
• BC Emergency medical assistants SARS-CoV-2 immunization order [updated 01-09-2022]
• BC Moderna redistribution guidelines [01-06-2022]
• BC Administrative circular [12-31-2021]
• BC 2021/22 seasonal influenza vaccine eligibility [10-00-2021]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [10-15-2021]
• BC Latex content in vaccines [10-00-2021]
• BC Immunization manual appendix A: informed consent (page 4) [updated 09-00-2021]
• BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [08-31-2021]
• BC COVID-19 vaccination: why your 2nd dose is important [08-27-2021]
• BC Vaccine SOP: cold chain incident reporting process [updated 07-21-2021]
• BC Pfizer vaccine sub dose vial reporting [07-13-2021]
• BC COVID-19 Pfizer vaccine partial tray ULT distribution guidelines [05-19-2021]
• BC Cold chain assets warranty contact information [05-05-2021]
• BC Vaccine SOP: return of materials to manufacturers [04-30-2021]

WHO

• Interim recommendations for the use of the Janssen Ad26.COV2.S (COVID-19) vaccine [06-06-2022]
• Annexes to the interim recommendations for use of the Janssen Ad26.COV2.S vaccine [06-06-2022]
• COVID-19 and mandatory vaccination: ethical considerations and caveats [05-30-2022]
• COVID-19 vaccine introduction and deployment costing tool (CVIC tool) version 2.3 [updated 04-21-2022]
- Injection safety in the context of coronavirus disease (COVID-19) vaccination: addendum to policy brief, 5 April 2022 [04-05-2022]
- Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19 [03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm [updated 03-15-2022]
- Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac [03-15-2022]
- Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
- Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
- Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
- NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
- Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing [01-21-2022]
- COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
- Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
- Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
- Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
- How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
- Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
- Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
- Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
- Technical note on delayed shipments for theChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
- Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
- AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
• Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
• COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
• Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• COVID-19 vaccine boosters [updated 06-24-2022]
• Stay up to date with your COVID-19 vaccines [updated 06-24-2022]
• COVID-19 vaccine reporting systems [updated 06-19-2022]
• Understanding viral vector COVID-19 vaccines [updated 06-16-2022]
• COVID-19 vaccination clinical & professional resources [updated 05-13-2022]
• Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 02-02-2022]
• Communication resources for COVID-19 vaccines [12-11-2021]
• COVID-19 vaccination program operational guidance [10-14-2021]
• Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol [no date]
• Interim guidance for routine and influenza immunization services during the COVID-19 pandemic [04-15-2021]
• Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK
• COVID-19 vaccination programme [updated 05-20-2022]
• Monitoring reports of the effectiveness of COVID-19 vaccination [updated 04-28-2022]
• National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [updated 04-01-2022]
• National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [updated 04-01-2022]
• National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [updated 04-01-2022]
• COVID-19 vaccination: information for healthcare practitioners [updated 03-10-2022]
• COVID-19: the green book, chapter 14a [updated 02-28-2022]
• COVID-19 vaccination: vaccine product information [02-23-2022]
• COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]
• COVID-19 vaccination: booster dose resources [updated 02-02-2022]
• National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]
• **COVID-19 vaccination: what to expect after vaccination** [updated 11-09-2021]
• **Monitoring of the effectiveness of COVID-19 vaccination** [09-14-2021]
• **COVID-19: vaccine surveillance strategy** [03-29-2021]

**ECDC**

• **Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines** [07-11-2022]
• **Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose** [04-28-2022]
• **Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA**, [updated 04-21-2022]
• **Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update** [03-14-2022]
• **Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA** [12-14-2021]
• **Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA** [10-15-2021]
• **Infographic: facilitating COVID-19 vaccination acceptance and uptake** [10-15-2021]
• **Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0** [10-08-2021]
• **Interim public health considerations for the provision of additional COVID-19 vaccine doses** [09-01-2021]
• **Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence** [07-22-2021]
• **Countering online vaccine misinformation in the EU/EEA** [06-29-2021]

**Australia**

• **ATAGI recommendations on the use of a booster dose of COVID-19 vaccine** [updated 07/013/2022]
• **COVID-19 vaccination – vaccine dose policy** [updated 07-13-2022]
• **Clinical recommendations for COVID-19 vaccines** [updated 07/12/2022]
• **COVID-19 vaccination – information on COVID-19 Pfizer (COMIRNATY) vaccine** [updated 07-12-2022]
• **ATAGI clinical guidance for COVID-19 vaccine providers** [02/23/2022]
• **COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination** [02-22-2022]
• **COVID-19 vaccination – updated provider kit for general practices** [12-14-2021]
Vaccinations - Specific populations

Canada (Federal)

- Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age [07-14-2022]
- Summary of NACI statement of July 14, 2022 [07-14-2022]
- NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age [archived] [modified 06-29-2022]
- NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2 [archived] [modified 06-29-2022]
- NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age [archived] [modified 03-17-2022]
- COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 03-11-2022]
- Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview [modified 02-03-2022]
- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [modified 02-02-2022]
- Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [updated 01-25-2022]
- NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]
- Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

Provinces and territories (other than Ontario)

- BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent [updated 07-08-2022]
- BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022 [updated 06-10-2022]
- BC COVID-19 vaccination for children age 5-11 frequently asked questions for community practitioners [03-07-2022]
- BC Residential care COVID–19 vaccination status [02-28-2022]

WHO

- Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons [10-25-2021]
- Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women [06-10-2021]
• **Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021** [04-26-2021]

**CDC**

- [COVID-19 vaccines while pregnant or breastfeeding](#) [updated 07-13-2022]
- [COVID-19 vaccines for people who would like to have a baby](#) [updated 07-13-2022]
- [Resources to promote the COVID-19 vaccine for children & teens](#) [07-01-2022]
- [COVID-19 vaccines for children and teens](#) [06-19-2022]
- [COVID-19 vaccine information for specific groups](#) [06-19-2022]
- [COVID-19 vaccine equity for racial and ethnic minority groups](#) [03-29-2022]
- [Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access](#) [01-20-2022]
- [Guidance for vaccinating older adults and people with disabilities at vaccination sites](#) [08-10-2021]
- [Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness](#) [04-30-2021]

**UK**

- [COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding](#) [04-11-2022]
- [COVID-19 vaccination: resources for children aged 5 to 11 years](#) [03-28-2022]
- [COVID-19 vaccination: resources for children and young people aged 12 to 17 years](#) [02-01-2022]
- [COVID-19 vaccination: guide for adults](#) [01-19-2022]
- [Interim public health considerations for COVID-19 vaccination of children aged 5-11 years](#) [12-01-2021]
- [Safety of COVID-19 vaccines when given in pregnancy](#) [04-30-2021]

**ECDC**

- [Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1](#) [02-18-2022]
- [COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose](#) [02-08-2022]
- [Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA](#) [06-01-2021]

### Vaccinations- Adverse Effects

**Canada (Federal)**

- [National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and...](#)
older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines [12-03-2021]

• Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021) [06-14-2021]

Provinces and territories (other than Ontario)

• BC Guidance document on the management of inadvertent vaccine errors [02-04-2022]
• BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine [06-11-2021]
• BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding [10-12-2021]
• BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults [no date]

CDC

• COVID-19 vaccine side effects in children and teens [06-19-2022]
• Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination [02-11-2022]
• Possible side effects after getting a COVID-19 vaccine [01-12-2022]
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]

WHO

• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• COVID-19 vaccines: safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women [07-12-2021]
• How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK

• Coronavirus (COVID-19) vaccine adverse reactions [07-07-2022]
• COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [03-21-2022]
• Myocarditis and pericarditis after COVID-19 vaccination [03-21-2022]
• COVID-19 vaccination: Guillain-Barré syndrome information for healthcare professionals [12-17-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia

• ATAGI clinical guidance on COVID-19 vaccine administration errors [04-08-2022]
• COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [04-28-2022]
• COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [03-01-2022]
Background Information/Case Definitions

Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [06-00-2022]

PHAC
- National case definition: coronavirus disease (COVID-19) [06-07-2022]
- COVID-19 case report form [01-11-2021]

CDC
- Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [12-23-2021]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 14.2) [06-02-2022]

PHAC
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [07-05-2022]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-12-2022]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [03-24-2022]
Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
COVID-19 new variants: knowledge gaps and research [01-12-2021]
Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]

CDC
Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19 [05-18-2022]
Testing strategies for SARS-CoV-2 [05-05-2022]
How to report COVID-19 laboratory data [04-04-2022]
Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
Guidance for reporting SARS-CoV-2 sequencing results [03-21-2022]
Evaluation for SARS-CoV-2 testing in animals [03-30-2022]
Guidance for general laboratory safety practices during the COVID-19 pandemic [03-02-2022]
Using antibody tests for COVID-19 [02-24-2022]
Interim guidelines for COVID-19 antibody testing; interim guidelines for COVID-19 antibody testing in clinical and public health settings [01-24-2022]
Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19) [12-13-2021]
Frequently asked questions on COVID-19 testing for laboratories [11-12-2021]
Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity [10-29-2021]
Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]
Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing [06-30-2021]
Variants and genomic surveillance for SARS-CoV-2 [04-02-2021]
Resources for laboratories working on coronavirus (COVID-19) [03-28-2021]
Information for laboratories about coronavirus (COVID-19) [03-28-2021]

UK
Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests [07-11-2022]
- Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices) [07-11-2022]
- Technical validation protocol for SARS-CoV-2 nucleic acid detection [07-11-2022]
- How tests and testing kits for coronavirus (COVID-19) work [02-14-2022]
- COVID-19: guidance for sampling and for diagnostic laboratories [03-29-2021]

**ECDC**

- The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates [05-10-2021]

**Australia**

- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

**Miscellaneous Guidelines**

**PHAC**

- COVID-19 and people with disabilities in Canada [07-06-2022]
- Individual public health measures [06-30-2022]
- Summary of evidence supporting COVID-19 public health measures [06-27-2022]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]

**Canadian provinces and territories (other than Ontario)**

- BC COVID-19 ethical decision-making framework [12-24-2020]

**WHO**

- Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
- Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
- ACT-Accelerator 'fair share asks' - by country [02-09-2022]
- WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
- Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

**CDC**

- Public health guidance for potential COVID-19 exposure associated with travel [updated 07-12-2022]
- Wildfire smoke and COVID-19: frequently asked questions and resources for air resource advisors and other environmental health professionals [01-31-2022]
- Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [01-21-2022]
- RRT composition: COVID-19 considerations [03-01-2021]

**ECDC**
- One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
- Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]

**Other**
- Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]

**Data & Surveillance**

**Canada**
- COVID-19 data trends [modified 06-24-2022]
- Mathematical modelling and COVID-19 [modified 04-01-2022]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

**WHO**
- Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance [04-14-2022]
- WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [02-15-2022]
- Public health surveillance for COVID-19: interim guidance [02-14-2022]
- End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States [01-21-2022]

**CDC**
- Wastewater surveillance data reporting & analytics [06-14-2022]
- National wastewater surveillance system (NWSS) [03-21-2022]
- Wastewater surveillance testing methods [01-26-2022]
- Public health interpretation and use of wastewater surveillance data [01-26-2022]
- Developing a wastewater surveillance sampling strategy [01-26-2022]
- Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
- COVID-19 serology surveillance [03-11-2021]
- Data visualization [02-16-2021]
- Large-scale geographic seroprevalence surveys [10-02-2020]

**ECDC**
- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
- COVID-19 variants: genomics confirmed case numbers [11-29-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
- COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
- Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]
- UK
  - COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]

**Variants – Omicron**

Canada
- SARS-CoV-2 variants: national definitions, classifications and public health actions [03-09-2022]

CDC
- Omicron variant: what you need to know [03-29-2022]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [06-28-2022]
- SARS-CoV-2 variants of public health interest [06-24-2022]

ECDC
- Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA [06-13-2022]
- Technical guidance for antigenic SARS-CoV-2 monitoring [06-07-2022]
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [01-27-2022]
- Methods for the detection and characterisation of SARS-CoV-2 variants – first update [12-20-2021]
- Threat assessment brief: implications of the further emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member states [updated 01-21-2022]

**Testing**

Canada
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [09-08-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

**Ontario Ministry of Health**
- COVID-19 provincial testing guidance. Version 15.0 [04-11-2022]
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing, version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening, Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]

**Canadian provinces and territories (other than Ontario)**
- BC COVID-19: viral testing guidelines for British Columbia [03-23-2022]
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]

**WHO**
- Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

**CDC**
- Testing strategies for SARS-CoV-2 [05-05-2022]
- Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community [04-04-2022]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
- Using antibody tests for COVID-19 [02-24-2022]
- SARS-CoV-2 antigen testing in long term care facilities [02-17-2022]
- Overview of testing for SARS-CoV-2 (COVID-19) [02-11-2022]
- Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [02-02-2022]
- Interim infection prevention and control recommendations to prevent SARS-CoV-2 spread in nursing homes: nursing homes & long-term care facilities [02-02-2022]
- CDC's diagnostic test for COVID-19 only and supplies [10-05-2021]
- Guidance for health departments about COVID-19 testing in the community [08-30-2021]
- CDC diagnostic tests for covid-19 [08-07-2021]
- Nucleic acid amplification tests (NAATs) [06-14-2021]
- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [06-14-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
- Serology testing for COVID-19 at CDC [11-03-2020]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [06-28-2022]
- SARS-CoV-2 variants of public health interest [06-24-2022]
- Investigation of SARS-CoV-2 variants of concern: variant risk assessments [06-24-2022]
- SARS-CoV-2 variant of concern diagnostic assurance [04-14-2022]
- Testing for coronavirus (COVID-19) before hospital [03-08-2022]
- Coronavirus COVID-19 serology and viral detection tests: technical validation reports [updated 02-18-2022]
- How tests and testing kits for coronavirus (COVID-19) work [02-14-2022]
- Investigation of SARS-CoV-2 variants of concern: technical briefings [09-17-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
- SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence [10-16-2020]

ECDC
- A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control [04-27-2022]
- Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise [04-27-2022]
- Considerations for the use of antibody tests for SARS-CoV-2 – first update [02-10-2022]
- Methods for the detection and identification of SARS-CoV-2 variants- first update [12-20-2021]
- Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories [12-20-2021]
- Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK [10-26-2021]
- Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings [05-06-2021]
- Considerations for the use of saliva as sample material for COVID-19 testing [05-03-2021]
- Considerations on the use of self-tests for COVID-19 in the EU/EEA [03-17-2021]
- Guidance for COVID-19 quarantine and testing of travellers [03-12-2021]
- Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA [02-16-2021]
- Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update [02-15-2021]
- COVID-19 testing strategies and objectives [09-18-2020]
- Objectives for COVID-19 testing in school settings [08-10-2020]
Australia

- PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests [06-20-2022]
- PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19) [01-28-2022]

Symptoms/Treatment

Canada

- Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply [06-22-2022]
- COVID-19 for health professionals: treatments [02-01-2022]
- Non-contact infrared thermometers (NCIT) [01-28-2021]

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 14.2 [updated 06-02-2022]
- COVID-19 patient screening guidance document version 5.0 [08-26-2021]

WHO

- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC

- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [06-15-2022]
- Clinical considerations for care of children and adults with confirmed COVID-19 [05-27-2022]
- Clinical care guidance for healthcare professionals about coronavirus (COVID-19) [04-29-2022]
- Caring for post-COVID conditions [updated 03-21-2022]
- Clinical care quick reference for COVID-19 [03-16-2022]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [updated 02-25-2022]
- Evidence used to update the list of underlying medical conditions that increase a person’s risk of severe illness from COVID-19 [02-15-2022]
- If you are sick or caring for someone [02-09-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [01-14-2022]
- **Ending isolation and precautions for people with COVID-19: interim guidance** [01-14-2022]
- **Standard operating procedure (SOP) for triage of suspected COVID-19 patients in non-US healthcare settings: early identification and prevention of transmission during triage** [10-18-2021]
- **Evaluating and caring for patients with post-COVID conditions: interim guidance** [06-14-2021]
- **Assessing risk factors for severe COVID-19 illness** [11-30-2020]

WHO

- **Therapeutics and COVID-19** [07-04-2022]
- **COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate** [02-04-2022]
- **COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery** [02-04-2022]
- **COVID-19 clinical management: living guidance** [11-23-2021]
- **Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection** [07-15-2021]
- **Hypertension and COVID-19** [06-17-2021]
- **WHO information note: COVID-19 considerations for tuberculosis (TB) care** [05-05-2021]
- **Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021** [04-24-2021]
- **WHO COVID-19 clinical care bundle** [04-23-2021]
- **Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance** [08-13-2020]

US NIH

- **COVID-19 treatment guidelines** [05-31-2022]

UK

- **COVID-19: migrant health guide** [03-08-2022]
- **COVID-19: long-term health effects** [04-30-2021]

Australia

- **Coronavirus (COVID-19) – identifying the symptoms** [last updated 07-05-2020]

**COVID-19 Diagnosis in Children**

Canada


WHO

- **COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021** [09-29-2021]

CDC

- **Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C)** [05-20-2021]
Other
- BC Children with immune compromise [11-30-2021]
- American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [06-10-2022]
- BC Pediatric clinical guidance for COVID-19 [09-27-2021]
- BC Guidance for newborn care, resuscitation procedures and lactation [06-11-2021]
- BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic [05-12-2021]

Post-COVID-19 Condition
Canada
- Post COVID-19 condition [06-27-2021]
Ontario
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]
WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]
CDC
- Post-COVID conditions; CDC Science [06-17-2022]
- Caring for post-COVID conditions [03-21-2022]
- Post-COVID conditions: information for healthcare providers [07-09-2021]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]
UK
- Long-term effects of coronavirus (long COVID) [05-25-2022]

Case Investigation & Contact Tracing
Canada
- Public health management of cases and contacts associated with COVID-19 [07-06-2022]
Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 14.2) [06-02-2022]
WHO
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]
CDC
- Quarantine and isolation [03-30-2022]
- Contact tracing resources for health departments [03-25-2022]
• Contact tracer’s interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
• Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2022]
• Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
• Contact tracing for COVID-19 [02-10-2022]
• Investigating a COVID-19 case [01-21-2022]
• Ending home isolation for persons with COVID-19 not in healthcare settings [01-14-2022]
• COVID-19 contact tracing communications toolkit for health departments [11-05-2021]
• Global contact tracing [01-15-2021]

UK

• COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [07-14-2022]
• People with symptoms of a respiratory infection including COVID-19 [06-10-2022]

Infection Prevention and Control

PHAC / Health Canada

• Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [07-06-2022]
• Coronavirus disease (COVID-19): prevention and risks [06-30-2022]
• Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]
• Infection prevention and control for COVID-19: interim guidance for outpatient and ambulatory care settings [01-25-2022]
• Infection prevention and control for COVID-19: interim guidance for home care settings [01-25-2022]
• Infection prevention and control for COVID-19: interim guidance for acute healthcare settings [01-25-2022]
• Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed – December 23, 2021 [12-24-2021]
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

Ontario

• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)

• BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]

WHO

Section II: Guidelines for Health Sectors

Healthcare Providers

Ontario Ministry of Health

- COVID-19 guidance: acute care v.8 [06-11-2022]
- COVID-19 Guidance: Personal Protective Equipment (PPE) for Health Care Workers and Health Care Entities version 1.0 [06-10-2022]
- COVID-19 guidance: independent health facilities; Version 4 [06-19-2020]

Canada

- COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO

- COVID-19 home care bundle for health care workers [02-09-2022]
- Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
- Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]

CDC

- Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [01-21-2022]
- Staff shortages [01-21-2022]
- Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]

UK

- COVID-19: managing healthcare staff with symptoms of a respiratory infection [04-01-2022]
Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- Ministry for seniors and accessibility COVID-19 guidance document for retirement homes in Ontario [06-24-2022]

PHAC

- COVID-19: guidance on pets and long-term care homes [07-20-2021]
- Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
- COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO

- Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC

- Correctional and detention facilities [06-10-2022]
- Guidance on prevention and management of COVID-19 in correctional and detention facilities [05-03-2022]
- Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [04-06-2022]
- How to protect yourself and others [02-25-2022]
- Investigating cases in homeless shelters [02-10-2022]
- Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
- Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
- Infection control for nursing homes [02-02-2022]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]
- Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness [04-30-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]

UK

- Infection prevention and control in adult social care: COVID-19 supplement [07-07-2022]
• Flu and acute respiratory illness in prisons and secure settings: information for staff [04-06-2022]
• COVID-19: guidance for hostel services for people experiencing homelessness and rough sleeping [04-04-2022]
• Visiting someone in prison [04-01-2022]
• Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [03-21-2022]
• COVID-19: provision of night shelters [03-10-2022]
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
• Infection control in prisons and places of detention [07-01-2011]

Other
• CSC Testing of inmates in federal correctional institutions for COVID-19 [updated 07-15-2022]

Section III: Guidelines for the Community

Travel, Transport & Borders

Ontario Ministry of Health
• Travelling during COVID-19 [06-17-2022]
• Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada
• Official global travel advisories [updated often]
• COVID-19: travel, testing, quarantine and borders [updated 07-07-2022]
• Provincial and territorial restrictions [06-27-2022]

CDC
• Requirement for proof of COVID-19 vaccination for air passengers [updated 07-14-2022]
• COVID-19 travel recommendations by destination [updated regularly]
• Stay up to date with your COVID-19 vaccines [06-24-2022]

UK
• COVID-19: guidance for people whose immune system means they are at higher risk [06-16-2022]
• People with symptoms of a respiratory infection including COVID-19 [06-10-2022]
• COVID-19 aviation health safety protocol: operational guidelines for the management of air passengers and aviation personnel in relation to the COVID-19 pandemic [05-11-2022]
• Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators [03-29-2022]
• Coronavirus (COVID-19): cruise ship travel [03-17-2022]

Other
• Emergency response plan and action checklist for use by air carriers in the event of a public health emergency [no date]
Schools / Childcare

Ontario Ministry of Health

- Management of cases and contacts of COVID-19 in Ontario version 14.2 [06-02-2022]
- COVID-19: health and safety measures at schools [03-31-2022]
- COVID-19: health and safety measures for child care [03-31-2022]

PHAC

- Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-02-2022]
- Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [01-07-2022]

CDC

- Guidance for K-12 schools and childcare programs [05-27-2022]
- Schools, child care, and colleges [05-27-2022]

UK

- Emergency planning and response for education, childcare, and children's social care settings [06-07-2022]

Back to Top

Mental Health /Addiction /Inequity

Ontario Ministry of Health


PHAC

- Helping people who use substances during the COVID-19 pandemic [07-06-2021]

Provinces & Territories (excluding Ontario)

- QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
- QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- QC Public health ethics and COVID-19: selected resources [11-00-2021]
- BC COVID-19: provincial episodic overdose prevention service (e-OPS) protocol [06-26-2020]

WHO

- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]
- Rise, respond, recover: renewing progress on women’s, children's and adolescent's health in the era of COVID-19 [12-00-2021]
- Social isolation and loneliness among older people: advocacy brief [07-29-2021]
- Smoking and COVID-19 [06-30-2020]
• Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
• COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

CDC / SAMHSA
• Disaster planning handbook for behavioural health service programs [03-00-2021]
• Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
• Considerations for crisis centers and clinicians in managing the treatment of alcohol or benzodiazepine withdrawal during the COVID-19 epidemic: March 19, 2020 [03-19-2020]
• Intimate partner violence and child abuse considerations during COVID-19 [no date]

UK
• Alcohol and drug misuse prevention and treatment guidance [03-07-2022]
• Every Mind Matters: looking after your mental health [no date]
• Domestic abuse: how to get help [11-11-2021]

Community

Ontario Ministry of Health
• COVID-19 public health measures and advice [no date]
• Guidance on community emergency evacuations: version 2 [05-16-2022]

PHAC
• COVID-19 and people with disabilities in Canada [07-06-2022]
• Summary of evidence supporting COVID-19 public health measures [06-27-2022]
• Reducing COVID-19 risk in community settings: a tool for operators [02-10-2022]
• Accessing additional public health support for First Nations and Inuit communities during COVID-19 [01-28-2022]
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO
• WHO mass gathering COVID-19 risk assessment tool: generic events, version 3 [06-16-2022]

CDC
• Information about COVID-19, pets, and other animals [04-14-2022]
• Operational considerations for community isolation centers [03-30-2022]
• Breastfeeding & caring for newborns [01-20-2022]
• Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-04-2021]
• Considerations for owners and operators of multifamily housing including populations at increased risk for complications from COVID-19 [05-05-2021]

UK
• Infection prevention and control in adult social care: COVID-19 supplement [07-07-2022]
- Living safely with respiratory infections, including COVID-19 [06-16-2022]
- COVID-19: guidance for providers of accommodation for asylum seekers [04-04-2022]

Businesses/Workplaces

Ontario Ministry of Health
- COVID-19 public health measures and advice [no date]
- COVID-19 worker and employee screening [06-11-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [04-14-2022]
- COVID-19 and workplace health and safety [03-28-2022]

WHO
- Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
- Workplaces & businesses: plan, prepare and respond [10-18-2021]
- Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

UK
- Reducing the spread of respiratory infections, including COVID-19, in the workplace [06-10-2022]

Masks (Non-Medical)

Ontario Ministry of Health
- Face coverings and face masks [06-11-2022]

PHAC
- COVID-19 mask use: advice for community settings [04-22-2022]

WHO
- What are relevant, feasible and effective approaches to promote acceptance, uptake and adherence to physical distancing measures for COVID-19 prevention and control? [00-00-2021]
- Mask use in the context of COVID-19 [12-01-2020]

CDC
- Your guide to masks [02-25-2022]

ECDC
- Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]

UK
- Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]
• The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]